Dr. Der-Yuan Wang the Chief of Section of Biologics & Advanced Therapeutic Product Analysis, Division of Research and Analysis for Food and Drug Administration (Taiwan FDA) of Taiwan joined us at World Vaccine Congress Asia in Singapore this June to address the issue of approval and safety surveillance of licensed vaccines in Taiwan.
Dr Wang covered the following points in this presentation:
- Resolving delays in application for approval of drug entry to market through a better understanding of Asian market needs
- Assessing issues in BLA evaluation, lot release and post-market surveillance of vaccines in the market
- Evaluating the current status and experiences from vaccine regulation and monitoring in Taiwan
Dr. Wang has over 15 years of experience in the industry and is currently responsible the market evaluation, lot release and post-market surveillance of biological products.
More regulatory updates will be discussed at next year's World Vaccine Congress Asia. To find out more, please visit our website: www.terrapinn.com/vaccineasia